Showing results (41-50 of 433) with videos related to
Sort By:
Pageof 44
Cancer Metastasis Reviews|July 2, 2017
Platelets, circulating tumor cells, and the circulomePreeti Kanikarla-Marie, Michael Lam, David G Menter, et al.Cancer Discovery|June 4, 2017
Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination StrategiesRaghav Sundar, David S Hong, Scott Kopetz, et al.Journal of Immunotherapy and Precision Oncology|January 15, 2025
Durable Remission After Targeted Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Case ReportDaniel A Fox, Deepak Bhamidipati, Scott Kopetz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2011
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesisChristopher Lieu, John Heymach, Michael Overman, et al.Cancer Biotherapy & Radiopharmaceuticals|January 14, 2020
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint PathwayMassimo Fantini, Justin M David, Christina M Annunziata, et al.Oncology (Williston Park, N.Y.)|May 23, 2008
Adjuvant chemotherapy for stage II colon cancerScott Kopetz, Daniela Freitas, Aknar F C Calabrich, et al.Journal of Hematology & Oncology|April 24, 2009
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapyDavid Z Chang, Vikas Kumar, Ying Ma, et al.Case Reports in Oncological Medicine|March 23, 2017
Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the LiteratureMaliha Khan, Krittiya Korphaisarn, Aneeqa Saif, et al.Statistics in Medicine|November 3, 2021
A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indicationsRongji Mu, Jin Xu, Rui Sammi Tang, et al.Gut|February 9, 2020
Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utilityMihnea Paul Dragomir, Scott Kopetz, Jaffer A Ajani, et al.Pageof 44